Regeneron Pharmaceuticals, Inc. · REGN
As of the latest run, Regeneron Pharmaceuticals, Inc. (REGN) scores 53/100 overall — a decent but mixed profile. Its strongest dimension: momentum (74/100); the one that most warrants attention: profitability (0/100).
Three pillars judge the company (profitability, growth, financial health), three judge the stock (valuation, momentum, risk). The score is recomputed every day from Yahoo Finance market data — the one shown above reflects today's state.
Momentum comes in at 74/100 — a well-oriented price trend. Growth comes in at 67/100 — sustained revenue growth. The risk pillar comes in at 65/100 — volatility kept in check by market standards.
The breakdown of each pillar — and a plain-English explanation of what it measures — is available in the full analysis, free and updated every day.
Profitability falls to 0/100 — thin margins or a disappointing return on capital.
No score replaces your own judgment: Stock Analyzer is a tool for analysis and understanding, not investment advice.